Neuropharmacology 2015-05-01

A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth.

Pei-Teh Chang, Rahul Subhash Talekar, Fan-Lu Kung, Ting-Rong Chern, Chen-Wei Huang, Qing-Qing Ye, Min-Yan Yang, Chao-Wu Yu, Shin-Yu Lai, Ravindra Ramesh Deore, Jung-Hsin Lin, Chien-Shu Chen, Grace Shiahuy Chen, Ji-Wang Chern

Index: Neuropharmacology 92 , 146-57, (2015)

Full Text: HTML

Abstract

Alzheimer's disease is a neurodegenerative disorder characterized by deposition of β-amyloid (Aβ) fibrils accompanied with progressive neurite loss. None of the clinically approved anti-Alzheimer's agents target both pathological processes. We hypothesized that conjugation of a metal chelator to destabilize Aβ fibrils (fAβs) and a long-chain fatty alcohol to induce neurite outgrowth may generate a novel molecular scaffold that targets both pathologies. The hydroxyalkylquinoline J2326 was designed and synthesized by joining an 11-carbon alcohol to 5-chloro-8-methoxyquinoline at the 2-position and its anti-neurodegenerative potentials in vitro and in vivo were characterized. It attenuated fAβ formation and disaggregated the existing fAβ zinc-dependently as well as zinc-independently. It also triggered extracellular signal-regulated kinase-dependent neurite outgrowth and increased synaptic activity in neuronal cells. In fAβ-driven neurodegeneration in vitro, J2326 reversed neurite collapse and neurotoxicity. These roles of J2326 were also demonstrated in vivo and were pivotal to the observed improvement in memory of mice with hippocampal fAβ lesions. These results show that the effectiveness of J2326 on fAβ-driven neurodegeneration is ascribed to its novel scaffold. This might give clues to evolving attractive therapy for future clinical trials. Copyright © 2015 Elsevier Ltd. All rights reserved.